Normal appearance
During cutaneous attack: Nonpitting edema
HAE ATTACKS MAY IMPACT YOUR PATIENTS MORE THAN YOU THINK
If left untreated or inadequately controlled, at least 3 in 4 attacks were severe enough to negatively impact quality of life, according to nearly 86% of patients, many of whom were using a preventive therapy.1
97% of patients agree nothing can be more convenient than the medication that sets them free from worrying about HAE attacks.2
* These findings are the result of an online survey conducted by The Harris Poll, sponsored by CSL Behring Inc, involving 100 U.S. adults ages 18+ who have been diagnosed by a healthcare professional with Hereditary Angioedema (HAE) (“people living with HAE”); and 150 licensed Allergists/Immunologists in the U.S. who have treated/managed at least 2 HAE patients in the past 12 months (“physicians”).
THE RIGHT THERAPY MATTERS TO BUILD AND MAINTAIN STEADY-STATE C1-INH FUNCTIONAL LEVELS
HAEGARDA replaces missing or dysfunctional C1-INH
- Functional C1‑INH levels ≥40% of normal are proposed to reduce the risk of HAE attacks3
- HAEGARDA replaces missing or dysfunctional C1-INH, which regulates the normal production of bradykinin
What made me try HAEGARDA? It’s the same protein my body is lacking.
-Zahra, HAEGARDA Advocate
C1-INH=C1 inhibitor.
HAE=hereditary angioedema.
The right therapy matters to get to steady state quickly4†
- Quick acting: steady-state C1-INH functional levels achieved in the first 2 weeks
- Administered subcutaneously, HAEGARDA 60 IU/kg maintained steady-state C1-INH functional levels above 40%4
- Steady state is expected within 3 to 4 doses4
† The plasma levels of C1-INH functional activity were evaluated in patients with type 1 or type 2 HAE in a Phase 3, placebo-controlled, crossover study. Patients received twice-weekly subcutaneous injections of HAEGARDA 40 IU/kg or 60 IU/kg for 16 weeks. The model-derived outcome is the steady-state C1-INH functional activity vs time.4
ROOT CAUSE OF HAE: DEFICIENT OR DYSFUNCTIONAL C1-INH5
Missing or nonfunctioning C1-INH is the root cause of HAE6
- C1-INH inactivates factors Xlla, plasmin, and kallikrein, thus preventing bradykinin overproduction7
- Low-level of dysfunctional C1-INH allows bradykinin production to go unregulated8
- Excess bradykinin increases vascular permeability, resulting in angioedema6
- HAE with normal C1-INH levels and function is very rare; lack of pivotal clinical trials hinders ability to clearly establish diagnosis9
OVERVIEW OF HEREDITARY ANGIOEDEMA (HAE)
Click on each part of the body to view common locations of swelling.10
The World Allergy Organization (WAO) guidelines recommend the use of C1-INH for HAE for long-term prophylaxis.11
The WAO Guideline for the Management of HAE states that patients should have HAE rescue medication available at all times.11
Epidemiology
- HAE is rare: affecting ~1 in 50K individuals. (1 in 10K – 1 in 150K worldwide)10
- HAE is an autosomal dominant genetic disorder resulting in deficiency (type I—85%) or dysfunction (type II—15%) of the C1-INH protein10
- C1-INH—a serine protease inhibitor—regulates the complement, contact, and coagulation cascades10
- Deficiency of functional C1-INH allows for uncontrolled activation of the contact system, resulting in increased vascular permeability and the classic symptoms of swelling10
Age of onset may vary
- Symptoms may occur at any age, but initial onset usually begins during childhood or adolescence (median = 6 years of age). Fifty percent of female and male patients are symptomatic at 12 and 13 years of age, respectively11
- HAEGARDA is approved for adults and children 6 years and older
Symptoms
- Unpredictable angioedema attacks of swelling in various body parts12
- Debilitation due to extreme pain, vomiting, nausea, and, if the airway is affected, asphyxiation12
- Patients may experience symptoms for 10 or more years before HAE is identified13
I remember the first time I went into the emergency room and the doctor said, ‘You have HAE,’ and…it was such a load removed from my shoulders because it was a doctor who knew what I had, and was able to treat it.
-Leah, HAEGARDA Advocate
What makes HAEGARDA different?
HAEGARDA is the HAE product that reduced HAE attacks by 95%.‡
LEARN MORE‡ Median reduction in the number of attacks with HAEGARDA 60 IU/kg vs placebo.
<FACE>
80%
OF PATIENTS EXPERIENCE FACIAL SWELLING
<THROAT>
50%
OF PATIENTS EXPERIENCE A LARYNGEAL ATTACK IN THEIR LIFETIME
Normal appearance
During laryngeal attack: voice change, hoarseness, swelling of larynx
<ABDOMEN>
70%TO>90%
EXPERIENCE AN ABDOMINAL ATTACK
Normal appearance
During abdominal attack: gastrointestinal pain, nausea, vomiting, swelling of abdomen